OAM
KLDO

Oxford Asset Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Oxford Asset Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,715
Closed -$89K – 1554
2019
Q4 		$89K Buy
+17,715
New +$113K ﹤0.01% 1624

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oxford Asset Management's KLDO Position: Q1 2020 in Review

Oxford Asset Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2020, closing a stake of 17,715 shares — an estimated $89K sold.

Oxford Asset Management first reported a position in KLDO in Q4 2019 and held it in 1 quarter. The position peaked at $89K in Q4 2019. 45 funds tracked by Wall St. Rank hold KLDO as of Q1 2020.

  • Oxford Asset Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 17,715 Kaleido Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $89K.
  • Oxford Asset Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's Kaleido Biosciences, Inc. Common Stock position peaked at $89K in Q4 2019.
  • 45 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.